Epizyme (NASDAQ:EPZM) PT Lowered to $8.00

Epizyme (NASDAQ:EPZMGet Rating) had its price target cut by HC Wainwright from $10.00 to $8.00 in a research report issued to clients and investors on Thursday, The Fly reports.

Other research analysts also recently issued reports about the company. StockNews.com assumed coverage on Epizyme in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Zacks Investment Research cut Epizyme from a “buy” rating to a “hold” rating and set a $1.75 price objective for the company. in a report on Friday, March 4th.

EPZM opened at $0.47 on Thursday. The stock’s 50-day moving average price is $1.00 and its 200 day moving average price is $2.15. Epizyme has a 12-month low of $0.46 and a 12-month high of $9.86. The firm has a market cap of $76.98 million, a price-to-earnings ratio of -0.19 and a beta of 1.28.

Epizyme (NASDAQ:EPZMGet Rating) last posted its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). Epizyme had a negative net margin of 671.02% and a negative return on equity of 2,459.33%. During the same period last year, the business posted ($0.69) earnings per share. On average, research analysts anticipate that Epizyme will post -1.16 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Metropolitan Life Insurance Co NY increased its position in shares of Epizyme by 18.3% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 19,570 shares of the biopharmaceutical company’s stock valued at $242,000 after purchasing an additional 3,029 shares during the period. Royal Bank of Canada grew its stake in Epizyme by 175.2% in the second quarter. Royal Bank of Canada now owns 6,147 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 3,913 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Epizyme by 12.2% during the 3rd quarter. Invesco Ltd. now owns 71,956 shares of the biopharmaceutical company’s stock worth $368,000 after acquiring an additional 7,844 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Epizyme by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 637,481 shares of the biopharmaceutical company’s stock worth $1,594,000 after purchasing an additional 8,403 shares during the last quarter. Finally, Point72 Hong Kong Ltd lifted its position in shares of Epizyme by 576.4% during the 3rd quarter. Point72 Hong Kong Ltd now owns 12,865 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 10,963 shares during the last quarter. 76.45% of the stock is currently owned by institutional investors and hedge funds.

About Epizyme (Get Rating)

Epizyme, Inc, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients.

Featured Stories

The Fly logo

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.